+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Candidiasis R&D Pipeline Analysis Report, H2-2018

  • ID: 4614176
  • Report
  • August 2018
  • Region: Global
  • 140 pages
  • VPA Research
1 of 3
Comprehensive Pipeline Review on Ongoing Clinical and Pre-Clinical Studies


  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Dermala Inc
  • iCo Therapeutics Inc.
  • Nosopharm SAS
  • Profem GmbH
  • MORE
Candidiasis Drug Development Pipeline Study is the latest publication from this researcher with comprehensive information of Candidiasis pipeline products.

The Candidiasis pipeline guide presents complete overview of drugs currently being developed for Candidiasis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Candidiasis pipeline candidate.
Research and Development progress along with latest news related to each of the Candidiasis pipeline candidates is included.

Major companies participating in therapeutic development of Candidiasis are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Candidiasis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Candidiasis clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Candidiasis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Candidiasis pipeline report includes
  • Panorama of Candidiasis pipeline markets including statistics on therapeutic drugs and companies involved
  • Candidiasis Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Candidiasis pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Candidiasis pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Candidiasis pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Candidiasis pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Candidiasis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Please Note: The report will be delivered in 2 working days after purchase
Note: Product cover images may vary from those shown
2 of 3


  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Dermala Inc
  • iCo Therapeutics Inc.
  • Nosopharm SAS
  • Profem GmbH
  • MORE
I. Key Findings

1. Companies Investing in Candidiasis Pipeline include
Number of Companies with Candidiasis projects in pre clinical Development
Number of Companies with Candidiasis projects in Clinical Development
Candidiasis Pipeline Companies based in Americas
Candidiasis Pipeline Companies based in Europe
Candidiasis Pipeline Companies based in Asia Pacific
Candidiasis Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Candidiasis Pipeline Agents in pre clinical/ Discovery stage of Development
Candidiasis Pipeline Agents in Clinical Development stage
Candidiasis Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Candidiasis Pipeline agents

II. Insights into Candidiasis Pipeline -

1. Disease Overview
Introduction to Candidiasis
Symptoms and Causes of Candidiasis
Treatment or Prevention Options for Candidiasis
Other Details
2. Phase wise Pipeline Compounds
Candidiasis Pipeline Pre Clinical/ Discovery stage Drugs
Candidiasis Pipeline Phase 1 stage Drugs
Candidiasis Pipeline Phase 2 stage Drugs
Candidiasis Pipeline Phase 3 stage Drugs
Candidiasis Pipeline Pre Registration stage Drugs
3. Company wise Candidiasis Pipeline Compounds
4. Candidiasis Pipeline by Mechanism of Action

III. Candidiasis Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Candidiasis Pipeline Company Briefs

V. Latest News and Developments in Global Candidiasis Pipeline Market

VI. Appendix
1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability
Note: Product cover images may vary from those shown
3 of 3
  • Acea Biotech Inc
  • Amplyx Pharmaceuticals Inc
  • Arietis Corp
  • Basilea Pharmaceutica
  • Biomar Microbial Technologies
  • Bionex Pharmaceuticals LLC
  • Biosergen AS
  • Cellix Bio Pvt Ltd
  • Chelation Partners Inc
  • Cidara Therapeutics Inc
  • Demegen
  • Dermala Inc
  • Ferrer Internacional, SA
  • Fox Chase Chemical Diversity Center Inc
  • Gedea Biotech AB
  • General Biologicals Corp
  • Hennepin Life Sciences LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma
  • Metabolab Inc
  • Nanomerics Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • NovaDigm Therapeutics Inc
  • Oryn Therapeutics
  • Profem GmbH
  • Sano Chemicals Inc
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Shaanxi Synthetic Pharmaceutical Co Ltd
  • TGV Laboratories Inc
  • Toltec Pharmaceuticals LLC
  • Viamet Pharmaceuticals Inc
  • Visterra Inc
  • Wellstat Vaccines LLC
Note: Product cover images may vary from those shown